Spinal cord atrophy, a measurable shrinking of the spinal cord’s cross-sectional area, produces symptoms that depend heavily on where the tissue loss occurs and which nerve pathways are affected. The most common signs include progressive limb weakness, increased muscle stiffness, altered sensation (numbness, tingling, or pain), and disruptions to bladder or bowel control. Because the spinal cord is a densely packed highway carrying motor commands downward and sensory signals upward, even modest tissue loss can produce symptoms that seem disproportionate to the size of the damage. What makes spinal cord atrophy particularly tricky is that it can appear across a wide range of conditions, from multiple sclerosis and ALS to vitamin deficiencies and rare genetic diseases, and its symptoms often overlap enough to delay the correct diagnosis for years.
Motor Symptoms Are Usually the First Thing People Notice
The spinal cord’s motor pathways run through its outer white matter and connect with motor neurons in the central gray matter. When atrophy affects these regions, the earliest and most recognizable sign is usually weakness. You might find that one leg drags slightly during walking, that grip strength has declined, or that tasks requiring fine coordination, like buttoning a shirt, have become unreliable. The weakness tends to be progressive rather than sudden, which is one reason people often attribute it to aging or deconditioning before seeking medical evaluation.
Alongside weakness, spasticity is extremely common. This involves an involuntary increase in muscle tone: your muscles feel stiff and resistant to movement, and reflexes become exaggerated. Spasticity is a hallmark of what clinicians call the upper motor neuron syndrome, which also includes loss of dexterity and the release of certain flexor reflexes that are normally suppressed.1Muscle & Nerve. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion In practical terms, you might notice that your legs stiffen when you try to walk, that your muscles jerk or spasm at night, or that your feet catch on surfaces. When spinal cord atrophy affects the cervical region (the neck), both arms and legs can be involved. When it affects the thoracic cord (mid-back), the legs are primarily affected while the arms are spared.
Sensory Changes That Go Beyond Numbness
Sensory symptoms from spinal cord atrophy are common but often harder to pin down. Numbness and tingling in the hands or feet are typical early complaints. Some people describe a band-like tightness around the torso, sometimes called the “MS hug,” though it occurs in other conditions affecting the cord as well. Reduced ability to sense temperature or light touch can develop gradually, and you might not realize it until you burn yourself without feeling it or notice that your feet feel like they are wrapped in thick socks.
Neuropathic pain is one of the most debilitating consequences of spinal cord damage. This is pain generated by the nervous system itself rather than by an injury to the body. It can feel like burning, stabbing, or electric shocks, and it tends to be persistent and difficult to treat because the underlying mechanisms are complex and still not fully understood.2PubMed Central. Neuropathic Pain After Spinal Cord Injury: Challenges and Research Perspectives The pain can occur at the level of the spinal cord damage or below it, and distinguishing between the two matters because they involve different pathological changes along the sensory pathways. One study tracking sensory system atrophy in spinal cord injury patients found progressive structural changes in sensory pathways even far from the injury site, with those changes closely linked to long-term sensory outcomes.3PubMed Central. Tracking sensory system atrophy and outcome prediction in spinal cord injury
Bladder, Bowel, and Sexual Dysfunction
These are among the most distressing symptoms of spinal cord atrophy, and also among the least discussed. The nerve pathways controlling the bladder, bowel, and sexual organs run through the spinal cord in close proximity to one another, so damage in one area frequently affects all three systems. Bladder dysfunction affects roughly three-quarters of people with spinal cord involvement in multiple sclerosis.4PubMed Central. Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease Symptoms can range from urgency and frequency to incomplete emptying or outright incontinence, depending on which cord segments are affected.
Bowel dysfunction in people with spinal cord pathology typically involves constipation, fecal incontinence, or both. Research has found that patients with spinal cord injury, MS, and several other neurological conditions experience serious upper and lower bowel dysfunctions that represent a major physical and psychological burden.5PubMed Central. Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson’s disease Sexual dysfunction is similarly prevalent and spans problems with arousal, sensation, and orgasm. All three of these functional areas are profoundly affected by spinal cord injuries, with the specific pattern depending on the level and severity of neurological damage.6Physical Therapy. Neurogenic Bladder, Neurogenic Bowel, and Sexual Dysfunction in People With Spinal Cord Injury
Why the Spinal Cord Shrinks in the First Place
Spinal cord atrophy is not a disease itself but a downstream consequence of ongoing damage to the cord’s tissue. The mechanisms differ by cause, but they converge on a common endpoint: loss of neurons, axons, or the myelin sheaths that insulate them, resulting in measurable shrinkage. In multiple sclerosis, atrophy appears to result from the cumulative effects of inflammation, demyelination, axonal injury, neuronal loss, and a process called Wallerian degeneration, in which the portion of a nerve fiber downstream from an injury breaks down.7Journal of Neuroimaging. Pathogenesis of Brain and Spinal Cord Atrophy in Multiple Sclerosis Iron deposition in the cord may also play a role, though the evidence is still emerging.
In ALS, the cord shrinks because motor neurons progressively die. In Friedreich’s ataxia, a genetic condition that usually begins in childhood or adolescence, cord thinning is already present at early disease stages and worsens over time.8PubMed Central. Progressive Spinal Cord Degeneration in Friedreich’s Ataxia: Results from ENIGMA-Ataxia Vascular causes such as spinal cord infarction, where the blood supply to the cord is interrupted, can produce atrophy in the chronic phase as dead tissue is resorbed.9PubMed. MRI of anterior spinal artery syndrome of the cervical spinal cord And a variety of metabolic and genetic diseases in adults, including certain leukodystrophies, mitochondrial diseases, and deficiency-related conditions, can cause cord atrophy as either a primary or secondary feature.
Multiple Sclerosis and the Cord
MS deserves its own discussion because it is the most common inflammatory cause of spinal cord atrophy, and because the relationship between cord shrinkage and disability has been studied extensively. In primary-progressive MS, development of cervical cord atrophy is associated with worsening disability and predicts further progression.10PubMed Central. Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis This means that measuring cord size over time is not just an academic exercise; it gives doctors a window into how the disease is likely to behave.
Research comparing different MS subtypes has found that cervical cord thinning correlates with most measures of clinical disability, and that including thoracic cord measurements alongside cervical ones improves the ability to capture the full picture of someone’s spinal cord involvement.11NeuroImage: Clinical. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability Separately, a study found that baseline cervical cord volume and the number of spinal cord segments affected by lesions were both relevant predictors of disease progression over two years.12PubMed. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis In MS specifically, MRI measurements at the C2 and C7 vertebral levels can distinguish patients with relapsing-remitting or secondary-progressive forms from healthy controls.13PubMed Central. MRI assessment of cervical spinal cord cross-sectional area in patients with multiple sclerosis
ALS and Spinal Cord Thinning
In amyotrophic lateral sclerosis, spinal cord atrophy reflects the loss of motor neurons that is central to the disease. Unlike MS, where inflammation is the main driver, ALS is a neurodegenerative process, and the cord shrinks steadily as the disease progresses. MRI measurements of spinal cord cross-sectional area in ALS patients have shown a negative correlation with disease duration, meaning the longer someone has had the disease, the smaller the cord tends to be.14PubMed. Spinal cord atrophy correlates with disease duration and severity in amyotrophic lateral sclerosis
The relationship goes beyond simple duration. A larger study using 3T MRI found that a larger upper cervical cord cross-sectional area was associated with shorter disease duration, better functional scores, and greater motor cortex thickness in the brain.15Scientific Reports. The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI More recently, researchers have looked not just at total cord size but specifically at gray matter atrophy within the cord and found that gray matter area at specific cervical levels correlates with muscle force in the corresponding limb segments and with overall functional status.16PubMed Central. Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis These findings have raised interest in using spinal cord measurements as a biomarker to track ALS progression or evaluate treatments in clinical trials.
How Spinal Cord Atrophy Is Measured
MRI is the primary tool for detecting and quantifying spinal cord atrophy. The most widely used measurement is the cross-sectional area of the cord at specific vertebral levels, particularly in the cervical region. A method called the mean upper cervical cord area (MUCCA) has emerged as an efficient and representative way to assess atrophy. One study comparing different MRI-based methods, including cervical cord volume and total cord volume, found that MUCCA performed similarly to the more complex volumetric approaches. The advantage is that it can be calculated from standard brain MRI sequences without needing a dedicated spine scan, and the measurement itself is relatively quick to perform.17American Journal of Neuroradiology. MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders
One challenge with measuring cord atrophy is reproducibility. Different MRI scanners, imaging protocols, and analysis software can produce slightly different numbers for the same person. A multicenter study testing repeatability on a single healthy volunteer scanned at multiple centers found that the best-performing methods achieved very low variability, with coefficients of variation under 1% when measurements were averaged over the full cervical cord from C1 to C7.18Frontiers in Neurology. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer Automated pipelines are also being developed that can segment the cord, label vertebral levels, and compute cross-sectional area without manual intervention, which would make large-scale studies and routine clinical use more practical.19PubMed Central. Automatic measure and normalization of spinal cord cross-sectional area using the pontomedullary junction
Blood Biomarkers That Signal Trouble
You cannot feel your spinal cord shrinking, and early atrophy may not produce obvious symptoms. This has driven interest in blood-based biomarkers that could flag ongoing damage before disability accumulates. Neurofilament light chain (NfL) is a protein released into the blood when nerve fibers are damaged, and elevated levels have emerged as one of the more promising markers. In MS patients, a study found that for every 10 picograms-per-milliliter increase in serum NfL, the spinal cord shrank an additional 0.19% over two years and 0.49% over five years. Patients with NfL levels above the 97.5th percentile had, on average, 1.7% lower spinal cord volume at two years and 2.5% lower at five years compared to those below that threshold.20Brain. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
In neuromyelitis optica spectrum disorder (NMOSD), a related but distinct inflammatory condition that often attacks the spinal cord aggressively, a reduction in NfL levels was associated with a roughly 7.5% loss of cervical spinal cord volume, suggesting that NfL dynamics can help predict structural outcomes even outside of MS.21Journal of Neuroimmunology. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder A simple blood draw to measure NfL is far easier to repeat than an MRI, which makes it a practical complement to imaging for monitoring disease activity.
When Atrophy Is Misidentified
One of the less appreciated aspects of spinal cord atrophy is how often it leads clinicians in the wrong diagnostic direction. A study of adult polyglucosan body disease (APBD), a rare genetic storage disorder, found that diagnosis was delayed by an average of nearly seven years. Every single patient in the study showed cervical spinal cord atrophy on MRI, yet all 30 were initially misdiagnosed. Common incorrect diagnoses included cerebral small vessel disease, multiple sclerosis, ALS, and peripheral neuropathies. The overlap in symptoms, such as progressive weakness, spasticity, and sensory loss combined with cord atrophy on imaging, made it easy to attribute the findings to a more common condition.
Metabolic and genetic diseases presenting in adulthood represent a broader category of underrecognized causes. These include leukodystrophies, mitochondrial diseases, and conditions related to specific nutritional deficiencies, all of which can produce spinal cord atrophy with or without signal abnormalities on MRI. Vitamin B12 deficiency, for example, is a well-known cause of spinal cord degeneration that is treatable when caught early. The practical takeaway is that when spinal cord atrophy appears on imaging and the usual suspects do not quite fit, rarer metabolic and genetic conditions deserve consideration, particularly if the presentation is slowly progressive and does not follow the typical pattern of MS or ALS.
What Atrophy Means for Recovery
Once spinal cord atrophy is established, it generally indicates permanent tissue loss, and the prospects for recovery depend heavily on the cause and the degree of thinning. A pediatric study of transverse myelitis, an acute inflammatory condition, illustrates this sharply. Among eight patients who developed spinal cord atrophy after their initial episode, seven showed no motor recovery at all. By contrast, among twelve patients whose cords did not atrophy, eleven recovered motor function. The odds of motor improvement were dramatically lower in the group with atrophy.22PubMed Central. Spinal Cord Atrophy and Early Motor Recovery following Transverse Myelitis in Pediatric Patients While this was a small study in a specific population, the pattern it illustrates, that established atrophy is a strong negative predictor of functional recovery, is consistent with what clinicians observe across conditions.
This does not mean that nothing can be done. Symptom management remains important even when the cord damage is irreversible. Spasticity, for instance, can be addressed through a range of strategies including stretching, physical modalities, medication, nerve blocks, and in severe cases surgical interventions.23PubMed Central. Spasticity Management after Spinal Cord Injury: The Here and Now The evidence base for physiotherapy specifically targeting spasticity in spinal cord conditions is, frankly, underwhelming: a systematic review of 17 trials found that only one demonstrated a clear treatment effect, which involved continuous passive motion of the ankle. The remaining trials were either inconclusive or showed the treatment was ineffective for reducing spasticity.24Spinal Cord. Physiotherapy interventions for the treatment of spasticity in people with spinal cord injury: a systematic review This does not mean physiotherapy is useless for cord-related disability broadly, but it does mean that expectations for spasticity reduction specifically should be tempered.
Gene Therapy and Neuroprotection Research
Active research is exploring whether the damage that leads to spinal cord atrophy can be slowed or even partially reversed at the cellular level. In animal models of spinal muscular atrophy, a severe genetic condition, gene therapy using a non-viral approach based on tetanus toxin C-fragment reduced the expression of genes involved in autophagy and programmed cell death in the spinal cord.25PubMed Central. Neuroprotective Effect of Non-viral Gene Therapy Treatment Based on Tetanus Toxin C-fragment in a Severe Mouse Model of Spinal Muscular Atrophy Separately, rat studies of spinal cord injury have compared direct gene therapy delivering a growth factor called GDNF against cell-based delivery using umbilical cord blood cells. Both approaches produced similar improvements in movement, though the cell-based method preserved more tissue and myelinated nerve fibers.26Spinal Cord. Adenoviral vector carrying glial cell-derived neurotrophic factor for direct gene therapy in comparison with human umbilical cord blood cell-mediated therapy of spinal cord injury in rat These are early-stage findings in animal models and have not yet translated to approved human therapies, but they point toward strategies that aim to protect neurons and support regrowth rather than simply managing the symptoms of tissue already lost.
How Symptoms Map to Cord Level
If you are trying to make sense of your own symptoms or someone else’s, one of the most useful things to understand is that the location of atrophy along the cord determines which functions are affected. The spinal cord is organized with remarkable specificity: each segment controls particular muscles and carries sensation from particular skin areas.
- Cervical cord (neck): Atrophy here tends to produce symptoms in both the arms and legs. Hand weakness, loss of fine motor control, and arm numbness are common alongside leg stiffness and walking difficulty.
- Thoracic cord (mid-back): Damage here usually spares the arms but affects the trunk and legs. You might notice balance problems, band-like sensations around the torso, and leg weakness or spasticity.
- Lumbar and sacral cord (lower back): Atrophy in this region affects the legs, bladder, bowel, and sexual function. Leg weakness may be accompanied by reduced reflexes rather than the exaggerated reflexes seen with higher-level damage, because the injury is closer to the actual motor neurons supplying the legs.
This segmental organization is why a thorough neurological examination can often localize the problem before imaging confirms it. It is also why the same disease can produce quite different symptom profiles in different people, depending on which parts of the cord bear the brunt of the damage. In Friedreich’s ataxia, for instance, cord thinning at all examined levels produces large effect sizes compared to healthy controls, with cross-sectional area reductions correlating strongly with disease severity.8PubMed Central. Progressive Spinal Cord Degeneration in Friedreich’s Ataxia: Results from ENIGMA-Ataxia In ALS, the cervical and upper thoracic cord are often most affected because the disease targets the motor neurons most densely packed in those regions.
Vascular causes add another layer of complexity. The anterior spinal artery supplies the front two-thirds of the cord, and when its blood flow is interrupted, the resulting anterior cord syndrome produces a characteristic pattern: motor paralysis and loss of pain and temperature sensation below the level of the injury, while the ability to sense vibration and position (carried in the back of the cord) is preserved. One case report described a patient whose congenital absence of the anterior spinal artery predisposed him to this pattern during a period of low blood pressure.27PubMed Central. Progressive Tetraparesis in a 57-Year-Old Man With Congenital Absence of an Anterior Spinal Artery: A Case of Anterior Spinal Cord Infarction The selective loss of some sensory modalities but not others is a clinical signature that points clinicians toward a vascular cause rather than an inflammatory or degenerative one.